Pacific Shuanglin Bio-pharmacy Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 5/6
Pacific Shuanglin Bio-pharmacy has been growing earnings at an average annual rate of 33.6%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 23.1% per year. Pacific Shuanglin Bio-pharmacy's return on equity is 10.6%, and it has net margins of 29.1%.
Anahtar bilgiler
33.6%
Kazanç büyüme oranı
26.2%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 11.3% |
Gelir büyüme oranı | 23.1% |
Özkaynak getirisi | 10.6% |
Net Marj | 29.1% |
Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
If EPS Growth Is Important To You, Pacific Shuanglin Bio-pharmacy (SZSE:000403) Presents An Opportunity
Oct 10Pacific Shuanglin Bio-pharmacy Co., LTD's (SZSE:000403) Shares May Have Run Too Fast Too Soon
Aug 16We Think Pacific Shuanglin Bio-pharmacy (SZSE:000403) Can Stay On Top Of Its Debt
Jul 22Is Now The Time To Put Pacific Shuanglin Bio-pharmacy (SZSE:000403) On Your Watchlist?
May 24Gelir ve Gider Dağılımı
Pacific Shuanglin Bio-pharmacy nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Sep 24 | 2,844 | 829 | 465 | 72 |
30 Jun 24 | 2,756 | 796 | 457 | 84 |
31 Mar 24 | 2,504 | 678 | 468 | 86 |
31 Dec 23 | 2,329 | 612 | 464 | 80 |
30 Sep 23 | 2,287 | 564 | 547 | 85 |
30 Jun 23 | 2,123 | 509 | 552 | 79 |
31 Mar 23 | 2,166 | 538 | 536 | 75 |
01 Jan 23 | 2,405 | 587 | 575 | 75 |
30 Sep 22 | 2,123 | 437 | 473 | 56 |
30 Jun 22 | 2,172 | 436 | 474 | 43 |
31 Mar 22 | 2,187 | 440 | 475 | 43 |
01 Jan 22 | 1,972 | 391 | 427 | 36 |
30 Sep 21 | 1,730 | 386 | 394 | 28 |
30 Jun 21 | 1,413 | 299 | 329 | 24 |
31 Mar 21 | 1,124 | 217 | 282 | 16 |
01 Jan 21 | 1,050 | 186 | 272 | 11 |
30 Sep 20 | 937 | 137 | 260 | 11 |
30 Jun 20 | 941 | 146 | 265 | 11 |
31 Mar 20 | 949 | 161 | 263 | 12 |
01 Jan 20 | 916 | 160 | 264 | 15 |
30 Sep 19 | 867 | 127 | 292 | 23 |
30 Jun 19 | 835 | 91 | 299 | 25 |
31 Mar 19 | 819 | 76 | 303 | 29 |
01 Jan 19 | 860 | 80 | 310 | 29 |
30 Sep 18 | 805 | 60 | 275 | 31 |
30 Jun 18 | 791 | 44 | 254 | 41 |
31 Mar 18 | 771 | 30 | 251 | 34 |
31 Dec 17 | 685 | 22 | 244 | 29 |
30 Sep 17 | 652 | 34 | 267 | 15 |
30 Jun 17 | 600 | 52 | 265 | 0 |
31 Mar 17 | 530 | 52 | 240 | 0 |
31 Dec 16 | 561 | 50 | 230 | 0 |
30 Sep 16 | 545 | 68 | 190 | 0 |
30 Jun 16 | 527 | 66 | 172 | 0 |
31 Mar 16 | 554 | 81 | 168 | 0 |
31 Dec 15 | 500 | 78 | 159 | 0 |
30 Sep 15 | 568 | 70 | 149 | 0 |
30 Jun 15 | 587 | 75 | 145 | 0 |
31 Mar 15 | 513 | 32 | 136 | 0 |
31 Dec 14 | 489 | 123 | 133 | 0 |
30 Sep 14 | 403 | 105 | 138 | 0 |
30 Jun 14 | 393 | 118 | 137 | 0 |
31 Mar 14 | 444 | 149 | 147 | 0 |
31 Dec 13 | 478 | 70 | 148 | 0 |
Kaliteli Kazançlar: 000403 has high quality earnings.
Büyüyen Kar Marjı: 000403's current net profit margins (29.1%) are higher than last year (24.7%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 000403's earnings have grown significantly by 33.6% per year over the past 5 years.
Büyüme Hızlandırma: 000403's earnings growth over the past year (47%) exceeds its 5-year average (33.6% per year).
Kazançlar vs. Sektör: 000403 earnings growth over the past year (47%) exceeded the Biotechs industry 0.08%.
Özkaynak Getirisi
Yüksek ROE: 000403's Return on Equity (10.6%) is considered low.